and tluedde@ukaachen.de 34 35 Precision treatment of cancer relies on genetic alterations which are diagnosed by molecular 36 biology assays. 1 These tests can be a bottleneck in oncology workflows because of high turna-37 round time, tissue usage and costs. 2 Here, we show that deep learning can predict point muta-38 tions, molecular tumor subtypes and immune-related gene expression signatures 3,4 directly 39 from routine histological images of tumor tissue. We developed and systematically optimized 40 a one-stop-shop workflow and applied it to more than 4000 patients with breast 5 , colon and 41 rectal 6 , head and neck 7 , lung 8,9 , pancreatic 10 , prostate 11 cancer, melanoma 12 and gastric 13 can-42 cer. Together, our findings show that a single deep learning algorithm can predict clinically ac-43 tionable alterations from routine histology data. Our method can be implemented on mobile 44 hardware 14 , potentially enabling point-of-care diagnostics for personalized cancer treatment 45 in individual patients. 46 Clinical guidelines recommend molecular testing of tumor tissue for most patients with advanced 47 209 The results are in part based upon data generated by the TCGA Research Network: http://can-210 cergenome.nih.gov/. Our funding sources are as follows. J.N.K.: RWTH University Aachen (START 211
solid tumors. However, in most tumor types, routine testing includes only a handful of altera-48 tions, such as KRAS, NRAS, BRAF mutations and microsatellite instability (MSI) in colorectal can-49 cer. While new studies identify more and more molecular features of potential clinical relevance, 50 current diagnostic workflows are not designed to incorporate an exponentially rising load of 51 tests. For example, in colorectal cancer, previous studies have identified consensus molecular 52 subtypes (CMS) as a candidate biomarker, but sequencing costs preclude widespread testing. 53
While comprehensive molecular and genetic tests are hard to implement at scale, histological 54 images stained with hematoxylin and eosin (H&E) are ubiquitously available. We hypothesized 55 that these routine images contain information about established and candidate biomarkers and 56 thus could be used for rapid pre-screening of patients, potentially alleviating the load of molec-57 ular assays. To test this, we developed, optimized and validated a deep learning algorithm to 58 determine molecular features directly from histology images. Deep learning with convolutional 59 neural networks has been used for tissue segmentation in cancer histology [15] [16] [17] or detecting mo-60 lecular changes in circumscribed use cases in a single tumor type 18-22 , but our aim was to use 61 deep learning in a pan-molecular pan-cancer approach. Our method is a 'one-stop-shop' work-62 flow: we collected large patient cohorts for individual tumor types, partitioning each cohort into 63 tion of microsatellite instability (MSI) in colorectal cancer as a clinically relevant benchmark task 20 66 and sampled a large hyperparameter space with different commonly used deep learning mod-67 els 16, 18, 20, 21 . Unexpectedly, 'inception' 23 and 'resnet' 24 networks, which had been the previous de-68 facto standard, were markedly outperformed by 'densenet' 25 and 'shufflenet' 14 were highly significantly detectable from histology alone, reaching AUCs of up to 0.82 in a three-79 fold patient-level cross-validation ( Fig. 1e) . 80
Having optimized our method in these use cases, we applied it to more than 4000 patients across 81 ten of the most prevalent solid tumor types from the TCGA reference database. We aimed to 82 predict all clinically and/or biologically relevant mutations with a prevalence above 2% and af-83 fecting at least four patients. The list of candidate mutations (Suppl. Table 2 ) also included all 84 point mutations targetable by FDA-approved drugs (www.oncokb.org). We found that in multiple 85 major cancer types, the genotype of point mutations was predictable directly from images. For 86 example, in lung adenocarcinoma (TCGA-LUAD 8 , N=464 patients), significant AUCs were achieved 87 for TP53 mutational status (AUC 0.71, Fig. 2a ) and EGFR mutational status (AUC 0.60), which is 88 targetable by clinically approved treatments. Also in colon and rectal cancer (TCGA-COAD and 89 TCGA-READ 27 , N=590 patients), standard-of-care genetic biomarkers 28 BRAF (AUC 0.66) and KRAS 90 (AUC 0.60) were significantly detectable, as were oncogenic driver mutations linked to tumor 91 aggressiveness, including CDC27 29 (AUC 0.70, Fig. 2b) . Similarly, in breast cancer (TCGA-BRCA 5 , for response to MEK inhibitors 30 , AUC 0.66) as well as PIK3CA (which is directly targetable by a 94 small molecule inhibitor 31 , AUC 0.63) were significantly detectable ( Fig. 2c) . In gastric cancer 95 (TCGA-STAD 13 , N=363 patients), mutations of MTOR -a candidate for targeted treatment 32 -96 were significantly detectable with a high AUC of 0.80 ( Fig. 2d) as were a range of driver mutations 97 including BRCA2 (AUC 0.67), PTEN (AUC 0.66), PIK3CA (AUC 0.65) among others. In head and neck 98 squamous cell carcinoma (TCGA-HNSC 7 , N=424 patients), genotype of CASP8, which is linked to 99 resistance to cell death 33 , was significantly detected with a high AUC of 0.72 (Suppl. Fig. 1a ). In 100 other tumor types such as melanoma (TCGA-SKCM 12 , N=429 patients), or lung squamous cell car-101 cinoma (TCGA-LUSC 9 , N=412 patients), few mutations were significantly detected (Suppl. Fig. 1b -102 c). Lung squamous cell carcinoma is known for its difficulty in molecular diagnosis and few mo-103 lecularly or genetically targeted treatment options even in clinical trials. Thus, it is plausible that 104 tumor histomorphology was not well correlated to mutations. In pancreatic adenocarcinoma 105 (TCGA-PAAD 10 , N=166 patients), identifying KRAS wild type patients is of high clinical relevance 106 because these patients are potential candidates for targeted treatment. Our method significantly 107 identified KRAS genotype with AUC 0.66 (Suppl. Fig. 1d ). Lastly, in prostate cancer (TCGA-PRAD 11 , 108 N=402 patients), our method detected targetable mutations from histology -most remarkably 109 PIK3CA, which was significantly detected with an AUC of 0.75 (Suppl. Fig. 1e ). Furthermore, 110 CDK12, which is linked to immune evasion in prostate cancer 34 was detected with an AUC of 0.71. 111
Together, these data show that deep learning can detect a wide range of targetable and poten-112 tially targetable point mutations directly from histology across multiple prevalent tumor types. 113
Next, we applied our method to a broader set of molecular signatures beyond single mutations. 114
We chose features with known biological and potential clinical significance which are currently 115 not part of clinical guidelines in most solid tumors. A major group of such features are immune-116 related gene expression signatures 3 of CD8-positive lymphocytes, macrophages, proliferation, in-117 terferon-gamma (IFNg) signaling and transforming growth factor beta (TGFb) signaling. These bi-118 ological processes are involved in response to cancer treatment, including immunotherapy. De-119 tecting their morphological correlates in histology images could facilitate the development of 120 more nuanced treatment strategies. Indeed, in lung adenocarcinoma signatures of proliferation, 6 macrophage infiltration and T-lymphocyte infiltration were significantly detectable from images 122 with high AUCs (Fig. 3a) . Similarly, significant AUCs for these biomarkers were achieved in colo-123 rectal cancer ( Fig. 3b) , breast cancer ( Fig. 3d ) and gastric cancer ( Fig. 3d) . In gastric cancer, we 124 additionally investigated a signature of stem cell properties (stemness) which was highly detect-125 able in images (AUC 0.76, Fig. 3d ). Recent studies have clustered tumors into comprehensive 126 'immune subtypes' 3 , but again this classification system relies on deep molecular profiling una-127 vailable in a clinical setting. We found that our method could detect these immune subtypes with 128 up to AUC 0.75 in lung adenocarcinoma ( Fig. 3a) , up to AUC 0.72 in colorectal cancer (Fig. 3b ) 129 and up to AUC 0.71 in breast cancer (Fig. 3c) . Together, these findings show that immunological 130 processes that are quantifiable by molecular profiling are also accessible to deep-learning-based 131 histology image analysis. 132
Finally, we investigated the use of deep learning on conserved molecular classes of tumors such 133 as recently identified TCGA subtypes 3 , pan-gastrointestinal subtypes 4 and consensus molecular 134 subtypes of colorectal cancer 6 . Few of these classification systems are currently incorporated in 135 clinical workflows, mainly because of the high cost and logistic effort associated with sequencing 136 technology. In our experiments, TCGA molecular subtypes LUAD1-6 were highly detectable in 137 histology images of lung adenocarcinoma ( Fig. 3a) with AUCs of up to 0.74. In colorectal cancer 138 ( Fig. 3b ) and gastric cancer ( Fig. 3d) , the pan-gastrointestinal (GI) subtypes GI-hypermutated-139 indel (GI-HM-indel), GI genome stable (GI-GS), GI-chromosomally instable (GI-CIN), GI-hypermu-140 tated-single-nucleotide variant predominant (GI-HM-SNV) and GI Epstein-Barr-Virus-positive (GI-141 EBV) were significantly detectable from histology. Correspondingly, in colorectal cancer, 'consen-142 sus molecular subtypes' 6 were detectable by deep learning (Fig. 3b) ing. We show that a unified workflow yields reliably high performance across multiple clinically 152 relevant scenarios. Compared to conventional genetic tests, our methodology enables detailed 153 prediction of the spatial heterogeneity of genotypes which is not possible in molecular bulk test-154 ing of tumor tissue. An example of this visualization is shown in (Fig. 4a-g) : Based only on a rou-155 tine histological image of colorectal cancer (Fig. 4a) , deep learning classifiers correctly predicted 156 CDC27 mutational status (Fig. 4b-c ) and consensus molecular subtype ( Fig. 4d-g) with a high prob-157 ability, while assigning a low probability to competing classes. 158
Image-based genotyping could be used for definitive testing once performance surpasses previ-159 ous tests, potentially disrupting clinical workflows Suppl. Fig. 3a-c . A limitation of our method is 160 the low AUC values for some molecular features, but re-training on larger cohorts with up to 161 10,000 patients per tumor type is expected to increase performance. 16 Scanned whole slide images of tissue slides stained with hematoxylin and eosin were acquired in 236 SVS format. Magnification was between 20x and 40x and corresponding resolution was between 237 0.25 and 0.51 micrometers per pixel (µm/px). All images were manually reviewed by a trained 238 observer who discussed non-trivial cases with an expert pathologist. After review by the expert 239 pathologist, only those images with tumor tissue on slide were used for downstream analysis. 240
The observer manually delineated tumor tissue on the slide which in most cases included more 241 than half of the total tissue. This region was then tessellated into square tiles of 256 µm edge 242 length. For the benchmark task, these images were resized 1.14 µm/ pixel to be consistent with 243 a previous study 20 ; for all subsequent tasks, images were processed at 0.5 µm/pixel. Some pa-244 tients in the TCGA archive had more than one slide per patient and in these cases, tiles from all 245 slides were pooled on a per-patient basis. From every slide, only a subset of tiles was used for 246 neural network training and prediction (default 1000 tiles per slide; values explored in hyperpa-247 rameter sampling: 250, 500 and 750). A target variable (e.g. a particular mutation) was matched 248 to each patient (see below) and all tiles corresponding to that patient inherited the label. The 249 patient cohort was then randomly split in three parts in such a way that each part contained 250 approximately the same number of patients with each label. These three parts of the patient 251 cohort were then used for three-fold patient-level cross-validation. Before training, each cohort 252 was randomly undersampled in such a way that the number of tiles per label was identical for The horizontal axis shows three-fold cross-validated area under the receiver operating curve 360 (AUC) as mean +/-95% bootstrapped confidence interval. 361
